Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma
British Journal of Surgery, Volume 105, No. 7, Year 2018
Notification
URL copied to clipboard!
Description
Background: Locoregional extension of intrahepatic cholangiocarcinoma (ICC) at the time of diagnosis results in a low resectability rate and poor prognosis. The aim of this retrospective study was to assess the efficacy of neoadjuvant chemotherapy for locally advanced ICC. Methods: All consecutive patients with ICC between 2000 and 2013 were included prospectively in a single-centre database and analysed retrospectively. Patients with locally advanced ICC considered as initially unresectable received primary chemotherapy, followed by surgery in those with secondary resectability. Results of patients who underwent surgery for locally advanced ICC were compared with those of patients with initially resectable ICC treated by surgery alone. Results: A total of 186 patients were included in the study. Of 74 patients with locally advanced ICC, 39 (53 per cent) underwent secondary resection after a median of six chemotherapy cycles. Patients in this group were younger (P = 0·030) and had more advanced disease than those who had surgery alone, and presented more frequently with lymphadenopathy (P = 0·010) and vascular invasion (P = 0·010). Postoperative morbidity and mortality were no different between the groups. The median survival of patients who had surgery after chemotherapy was 24·1 months, and that of patients who had surgery alone was 25·7 months (P = 0·391). Conclusion: Patients with locally advanced ICC treated by surgery following neoadjuvant chemotherapy had similar short- and long-term results to patients with initially resectable ICC who had surgery alone. Neoadjuvant chemotherapy as a first-line treatment for locally advanced ICC may be an effective downstaging option, facilitating secondary resectability in patients with initially unresectable disease. © 2017 BJS Society Ltd Published by John Wiley & Sons Ltd
Authors & Co-Authors
Pittau, Gabriella
France, Paris
Ap-hp Assistance Publique - Hopitaux de Paris
Allard, Marc Antoine
France, Paris
Ap-hp Assistance Publique - Hopitaux de Paris
Pereira, Bruno
France, Clermont-ferrand
Centre Hospitalier Universitaire de Clermont-ferrand
Serji, Badr
France, Paris
Ap-hp Assistance Publique - Hopitaux de Paris
Vi̇Bert, Éric
France, Paris
Ap-hp Assistance Publique - Hopitaux de Paris
Castaing, Denis
France, Paris
Ap-hp Assistance Publique - Hopitaux de Paris
Adam, Reńe A.
France, Paris
Ap-hp Assistance Publique - Hopitaux de Paris
Cherqui, Daniel
France, Paris
Ap-hp Assistance Publique - Hopitaux de Paris
Sa-Cunha, Antonio
France, Paris
Ap-hp Assistance Publique - Hopitaux de Paris
Statistics
Citations: 165
Authors: 9
Affiliations: 2
Identifiers
Doi:
10.1002/bjs.10641
ISSN:
00071323
Research Areas
Cancer
Health System And Policy
Study Design
Cohort Study